Evidence map›Paper›PMID 40826891›Full record

ArticleAmerican journal of epidemiology2025

The impact of cancer survivors' extra risk of noncancer mortality on net survival estimation.

Laura Botta, Riccardo Capocaccia, Alice Bernasconi, Silvia Rossi, Jaume Galceran, Luigino Dal Maso, Come Lepage, Florence Molinié, Anne-Marie Bouvier, Rafael Marcos-Gragera and 7 more

Abstract read
In one paragraph

Article in American journal of epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Laura BottaEvaluative Epidemiology Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0002-2793-5338
Riccardo CapocacciaEditorial Board, Epidemiologia e Prevenzione, Milan, Italy.ORCID 0000-0002-1455-1992
Alice BernasconiEvaluative Epidemiology Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0001-8522-6882
Silvia RossiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.ORCID 0000-0002-9815-2904
Jaume GalceranTarragona Cancer Registry, Cancer Epidemiology and Prevention Service, Hospital Universitari Sant Joan de Reus, Reus, Spain.ORCID 0000-0002-1584-7293
Luigino Dal MasoCancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.ORCID 0000-0001-6163-200X
Come LepageINSERM CTM UMR 1231 EPICAD, University of Burgundy, Dijon, France.ORCID 0000-0001-9211-4707
Florence MoliniéFRANCIM Network, Toulouse F-31073, France.ORCID 0000-0002-0645-4017
Anne-Marie BouvierINSERM CTM UMR 1231 EPICAD, University of Burgundy, Dijon, France.ORCID 0000-0001-9070-1027
Rafael Marcos-GrageraEpidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology (ICO), Girona Biomedical Research Institute (IdiBGi-CERCA), University of Girona, Josep Carreras Leukemia Research Institute (IJC), Girona, Spain.ORCID 0000-0001-9824-3657
Claudia VenerEpidemiology and Prevention Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0001-7351-8634
Marcela GuevaraCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.ORCID 0000-0001-9242-6364
Deirdre MurrayNational Cancer Registry Ireland, Cork, Ireland.ORCID 0009-0006-3868-4737
Rosalia RagusaCatania-Messina-Enna CR, Azienda Ospedaliero Universitaria Policlinico, Catania, Italy.ORCID 0000-0002-0964-3438
Gemma GattaEvaluative Epidemiology Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0003-4160-6458
Valerie JoosteINSERM CTM UMR 1231 EPICAD, University of Burgundy, Dijon, France.ORCID 0000-0002-9902-0700
EUROCARE-6 WG

Funding

French Institut National du Cancer 2018-178Innovative Partnership for Action Against Cancer 801520 HP-JA-2017Italian Association for Cancer Research 28893Italian Association of Cancer Research (AIRC) 2020 ID.24933
6 · The paper itself

Abstract

Relative survival (RS) with the general population as the reference is commonly used to estimate net survival (NS). However, cancer patients may face an increased risk of noncancer death compared to cancer-free individuals. We evaluate the impact of considering this relative risk (RR) on NS estimation. First, we compared selected NS values to generated RS under various theoretical scenarios, considering different RR, NS, age at diagnosis, time since diagnosis, and sex. Then, differences between NS and RS for 3 cancers were analyzed from cure model-based estimates using EUROCARE-6 data. We observed differences between RS and the true value of NS, larger for longer time since diagnosis, older patients, and higher NS. For head and neck cancer, the smallest differences were for young female patients at 5 years from diagnosis (4%) and the highest (32%) for older patients. For colorectal cancer, differences were <7% for all ages, both sexes, and times since diagnosis and for breast cancer, differences were <5% except for older patients after 5 years. If RR > 1, RS underestimates NS. Our findings aim to correctly interpret the differences between RS and NS, and contextualize the possible biases of assuming RS as a proxy for cancer-specific survival.

Indexed as

Cancer SurvivorsNeoplasmsAdultAgedAged, 80 and overAge FactorsBreast NeoplasmsColorectal NeoplasmsFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedSurvival AnalysisYoung Adultnet survivalpopulation-based cancer registryrelative risk of noncancer death for cancer patients compared to general populationrelative survival

Identifiers

PMID40826891
PMCPMC12634115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.